Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
COSCIENS Biopharma ( (TSE:CSCI) ) has provided an update.
COSCIENS Biopharma Inc. has received director nominations from Goodwood Fund and Puccetti Funds Management for its upcoming Annual and Special Meeting of Shareholders. The company’s board is reviewing the nominations and is committed to acting in the best interests of COSCIENS and its shareholders, with further updates to be provided. This development could influence the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relationships.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life sciences company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. The company utilizes proprietary extraction technology to produce active ingredients from renewable plant resources, which are used in leading skincare brands and are being developed for nutraceutical and pharmaceutical applications. COSCIENS also offers macimorelin, the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency. The company is listed on NASDAQ and the Toronto Stock Exchange under the ticker symbol ‘CSCI’.
YTD Price Performance: 24.17%
Average Trading Volume: 2,268
Technical Sentiment Signal: Sell
Current Market Cap: C$15.35M
Find detailed analytics on CSCI stock on TipRanks’ Stock Analysis page.